USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: TUNITAS THERAPEUTICS, INC.
City: San Francisco
State: CA
Zip+4: -
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $743,494.00 2
SBIR Phase II $6,000,000.00 2
STTR Phase I $172,386.00 1
STTR Phase II $1,699,968.00 1

Award List:

Cat allergen-human Fc-gamma1 chimeric proteins to treat cat allergy

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Nolan Sigal
Award Amount: $300,000.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this SBIR proposal is to develop and commercialize a new approach for allergen specific immunotherapy as treatment for cat allergy. This proposal will provide a novel therapeutic for a very importan t inhalant allergen and serve as a model… More

Allergen???Fc-gamma1 proteins to treat food allergy

Award Year / Program / Phase: 2010 / STTR / Phase I
Agency: HHS
Research Institution: University Of California Los Angeles
Principal Investigator: Nolan Sigal – 650-887-4747
Award Amount: $172,386.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): The goal of this proposal is to develop and commercialize a novel approach for allergen specific immunotherapy as treatment for severe food allergy. Food allergy affects about 3.5% of the US population and 6% to 8% ofyoung children. It is clearly on the rise.… More

A Human Fc Bifunctional Fusion Protein to Treat Severe Allergic Asthma

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Nolan Sigal – 650-887-4747
Award Amount: $443,494.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this proposal is to develop and commercialize a novel biologic therapy for the treatment of allergic disease and particularly allergic asthma. Specifically, this proposal will provide the critical immunogenicity, mechanistic and biomarker data… More

A therapeutic Fc gamma Fel d1 chimeric protein vaccine to treat cat allergy

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Nolan Sigal – 650-887-4747
Award Amount: $3,000,000.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this phase 2 SBIR proposal is to develop and commercialize a novel biologic for allergen- specific immunotherapy as effective treatment for cat allergy/asthma. Cat allergy is common, with 17% of USpopulation, age 6-59, being skin test… More

Therapeutic peanut allergen Fc gamma chimeric proteins to treat peanut allergy

Award Year / Program / Phase: 2012 / STTR / Phase II
Agency: HHS
Research Institution: UNIVERSITY OF CALIFORNIA LOS ANGELES
Principal Investigator: Nolan Sigal – 650-887-4747
Award Amount: $1,699,968.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this Phase 2 STTR is to develop and commercialize a novel approach for allergen specific immunotherapy as a treatment for severe food allergy. Currently treatment to prevent severe food reactions isa major unmet need. There is no effective… More

A Human Fc Bifunctional Fusion Protein to Treat Severe Allergic Asthma

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: Nolan Sigal – 650-887-4747
Award Amount: $3,000,000.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this phase 2 SBIR proposal is to position our novel biologic GE2 for human clinical trials in allergic disease though the completion of critical preclinical development research activities. GE2, a genetically engineered human fusion protein… More